Dasatinib Overrides Imatinib Resistance Mediated by the F359I Residue Mutation in Two Patients with Chronic Myeloid Leukemia

Publisher： Karger

E-ISSN： 1421-9662|127|1|56-59

ISSN： 0001-5792

Source： Acta Haematologica, Vol.127, Iss.1, 2011-11, pp. : 56-59

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nilotinib Can Override Dasatinib Resistance in Chronic Myeloid Leukemia Patients with Secondary Resistance to Imatinib First-Line Therapy

By  

Acta Haematologica, Vol. 118, Iss. 3, 2007-09 ,pp. : 162-164

Karger

Access to resources Recommend Favorite

Apoptosis-Related Gene Expression Profile in Chronic Myeloid Leukemia Patients after Imatinib Mesylate and Dasatinib Therapy

By  

Acta Haematologica, Vol. 133, Iss. 4, 2015-02 ,pp. : 354-364

Karger

Access to resources Recommend Favorite

Dasatinib in the Treatment of Chronic Myeloid Leukemia

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 99-105

Bentham Science Publishers

Access to resources Recommend Favorite

Molecular Surveillance of Chronic Myeloid Leukemia Patients in the Imatinib Era – Evaluation of Response and Resistance

By  

Acta Haematologica, Vol. 112, Iss. 1-2, 2004-06 ,pp. : 85-92

Karger

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite